Products

Discover nanopore sequencing

What can it do? How does it work? Our platform performance and accuracy

Explore products

Prepare Sequence Analyse
Store Resources Support About

Filippo Martignano

Nanopore sequencing and liquid biopsy: copy number variation analysis of short cell-free DNA from plasma of lung cancer patients

Compared to tissue biopsies, ‘liquid biopsy is very very non-invasive, you can easily get out a lot of samples to strictly monitor the tumour evolution’– this is particularly important for personalised medicine in future.

Why Nanopore for sequencing cfDNA? Filippo explained its benefits: portability, low instrumentation costs, and real-time sequencing.

Filippo is investigating copy number variation (CNV), using shallow whole-genome nanopore sequencing, in cfDNA samples. Using the MinION or GridION devices, he sequenced samples from healthy control individuals and lung cancer patients, multiplexing 5 samples per flow cell (prepared using ligation sequencing and barcoding).

Only 2 M reads (out of the total 14 M reads) was sufficient to obtain a similar CNV profile, with 98% concordance to the 14 M read set. This could be achieved in 3 hours.

Nanopore real-time sequencing and analysis (NanoGLADIATOR) enables rapid CNV detection, in only 3 hours. This is ‘incredibly fast’ compared to short-read analysis which can take days.

See his recent publication on this research in the Resource Centre.

Read his recent blog